Key result
Improving the implementation of fixed dose combination therapy for cardiovascular disease requires country-specific health systems analyses to design appropriate strategies.
Why the study?
Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy has been poor.
Population
Stakeholders from academia, government, and NGOs
Design
Symposium report
Authors
Loading...
FDC implementation barriers persist; leaves open effective country-level strategies pending targeted health systems research.
Improving the poor uptake of fixed-dose combination therapies for CVD requires country-specific health systems analyses and strategies addressing availability, accessibility, affordability, and adherence.
Webster et al. (2020) studied Cardiovascular disease. Fixed dose combination therapy (FDCs) was evaluated. Improving the implementation of fixed dose combination therapy for cardiovascular disease requires country-specific health systems analyses to design appropriate strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: